{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:08:01Z","timestamp":1781626081542,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic lymphocytic leukemia (CLL) is characterized by aberrant B-cell receptor (BCR) signalling and resistance to apoptosis. Patients with CLL present varied responses to BCR-targeted therapies, this emphasises the need for personalised treatment strategies. The immunophenotype of B cell in patients with CLL may offer valuable insights into disease heterogeneity and immunotherapeutic strategies. In this study, we investigated the prognostic value of B cell subsets in relation to clinical parameters such as Rai stage, \u03b2\u2082-microglobulin (B2M) levels and the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) in untreated patients with CLL. The levels B cell subsets were measured using multicolor flow cytometry. Interestingly, patients with CLL had significantly increased levels of na\u00efve B cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). As expected, patients with CLL had significantly decreased levels of marginal zone B cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0059), non-class switched memory B cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0010), and class switched memory B cells (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Moreover, after adjusting for age and sex, class-switched memory B cells were positively associated with the Rai stage (\u03b2\u2009=\u20090.1455,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0466). In contrast, non-class switched memory B cells inversely correlated with the Chronic Lymphocytic Leukemia International Prognostic Index (\n                    <jats:italic>r<\/jats:italic>\n                    = -0.79,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). These findings suggest that memory B-cell subset profiles may provide valuable prognostic significance in patients with CLL.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-02002-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:15:12Z","timestamp":1766564112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of memory B cell subpopulation in patients with chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"26","author":[{"given":"Aviwe","family":"Ntsethe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani Brian","family":"Nkambule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"25","key":"2002_CR1","first-page":"2745","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. J Am Soc Hematol. 2018;131(25):2745\u201360.","journal-title":"J Am Soc Hematol"},{"issue":"4","key":"2002_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390(4):326\u201337.","journal-title":"N Engl J Med"},{"key":"2002_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/9783527814695.ch9","volume":"4","author":"WJ Fairbrother","year":"2019","unstructured":"Fairbrother WJ, Leverson JD, Sampath D, Souers AJ. Discovery and development of Venetoclax, a selective antagonist of BCL-2. Success Drug Discovery. 2019;4:225\u201345.","journal-title":"Success Drug Discovery"},{"issue":"19","key":"2002_CR4","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, Von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"2002_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):535\u201352.","journal-title":"Lancet Oncol"},{"issue":"9980","key":"2002_CR6","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus Chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873\u201383.","journal-title":"Lancet"},{"key":"2002_CR7","first-page":"4","volume":"49","author":"PJ Trivedi","year":"2023","unstructured":"Trivedi PJ, Patel DM, Kazi M, Varma P. Cytogenetic heterogeneity in chronic lymphocytic leukemia. J Assoc Genet Technol. 2023;49:4\u20139.","journal-title":"J Assoc Genet Technol"},{"issue":"5","key":"2002_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"JA Burger","year":"2020","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460\u201373.","journal-title":"N Engl J Med"},{"key":"2002_CR9","doi-asserted-by":"crossref","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. 1975.","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"issue":"10","key":"2002_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1080\/10428194.2022.2090551","volume":"63","author":"A Paulus","year":"2022","unstructured":"Paulus A, Malavasi F, Chanan-Khan A. CD38 as a multifaceted immunotherapeutic target in CLL. Leuk Lymphoma. 2022;63(10):2265\u201375.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2002_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1186\/s12885-022-10223-0","volume":"22","author":"ZA Mkhwanazi","year":"2022","unstructured":"Mkhwanazi ZA, Nyambuya TM, Mfusi SA, Nkambule BB. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. BMC Cancer. 2022;22(1):1218.","journal-title":"BMC Cancer"},{"issue":"1","key":"2002_CR12","doi-asserted-by":"publisher","first-page":"6545921","DOI":"10.1155\/2020\/6545921","volume":"2020","author":"L Karabon","year":"2020","unstructured":"Karabon L, Partyka A, Ciszak L, Pawlak-Adamska E, Tomkiewicz A, Bojarska-Junak A, et al. Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients. J Immunol Res. 2020;2020(1):6545921.","journal-title":"J Immunol Res"},{"key":"2002_CR13","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432.","journal-title":"Leuk Res"},{"issue":"12","key":"2002_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1084\/jem.20120833","volume":"209","author":"M Seifert","year":"2012","unstructured":"Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, D\u00fcrig J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183\u201398.","journal-title":"J Exp Med"},{"issue":"3","key":"2002_CR15","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/cimb46030112","volume":"46","author":"A Ntsethe","year":"2024","unstructured":"Ntsethe A, Mkhwanazi ZA, Dludla PV, Nkambule BB. B cell subsets and immune checkpoint expression in patients with chronic lymphocytic leukemia. Curr Issues Mol Biol. 2024;46(3):1731\u201340.","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"2002_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/biomedicines13030741","volume":"13","author":"A Ntsethe","year":"2025","unstructured":"Ntsethe A, Dludla PV, Nkambule BB. Impact of protein kinase C activation and monoclonal antibodies on immune checkpoint regulation and B cell function in patients with chronic lymphocytic leukemia. Biomedicines. 2025;13(3):741.","journal-title":"Biomedicines"},{"issue":"1","key":"2002_CR17","first-page":"A21","volume":"1","author":"T Jaatinen","year":"2007","unstructured":"Jaatinen T, Laine J. Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient. Curr Protoc Stem Cell Biol. 2007;1(1):A21\u2013214.","journal-title":"Curr Protoc Stem Cell Biol"},{"issue":"12","key":"2002_CR18","first-page":"5446","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National cancer Institute\u2013Working group 1996 guidelines. Blood J Am Soc Hematol. 2008;111(12):5446\u201356.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"2002_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ajh.23214","volume":"87","author":"AW Hauswirth","year":"2012","unstructured":"Hauswirth AW, Almeida J, Nieto WG, Teodosio C, Rodriguez-Caballero A, Romero A, et al. Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal Circulating B-cell subsets. Am J Hematol. 2012;87(7):721\u20134.","journal-title":"Am J Hematol"},{"key":"2002_CR20","doi-asserted-by":"publisher","first-page":"1020740","DOI":"10.3389\/fonc.2022.1020740","volume":"12","author":"T Andrieu","year":"2022","unstructured":"Andrieu T, Mondi\u00e8re P, Jouve P-E, Dussurgey S, Malassign\u00e9 V, Servanton H, et al. Mass cytometry analysis reveals attrition of na\u00efve and anergized self-reactive non-malignant B cells in chronic lymphocytic leukemia patients. Front Oncol. 2022;12:1020740.","journal-title":"Front Oncol"},{"issue":"21","key":"2002_CR21","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/cancers15215160","volume":"15","author":"M Cerreto","year":"2023","unstructured":"Cerreto M, Fo\u00e0 R, Natoni A. The role of the microenvironment and cell adhesion molecules in chronic lymphocytic leukemia. Cancers. 2023;15(21):5160.","journal-title":"Cancers"},{"key":"2002_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2018.00683","volume":"9","author":"W Darwiche","year":"2018","unstructured":"Darwiche W, Gubler B, Marolleau J-P, Ghamlouch H. Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective. Front Immunol. 2018;9:683.","journal-title":"Front Immunol"},{"issue":"3","key":"2002_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48(3):253\u201364.","journal-title":"Nat Genet"},{"key":"2002_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3389\/fimmu.2020.00736","volume":"11","author":"D Bautista","year":"2020","unstructured":"Bautista D, V\u00e1squez C, Ayala-Ram\u00edrez P, T\u00e9llez-Sosa J, Godoy-Lozano E, Mart\u00ednez-Barnetche J, et al. Differential expression of IgM and IgD discriminates two subpopulations of human Circulating IgM\u2009+\u2009IgD\u2009+\u2009CD27\u2009+\u2009B cells that differ phenotypically, functionally, and genetically. Front Immunol. 2020;11:736.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-02002-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:44:20Z","timestamp":1781624660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-02002-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-02002-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (study approval no. BE456\/18).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"80"}}